New AIDS Drug Receives FDA Approval

Article

WASHINGTON, DC-A new nucleotide analog has been passed by the US Food and Drug Administration (FDA) in an attempt to help the current list of anti-viral AIDS drugs.

Viread, manufactured by Gilead Sciences of Foster City, Calif., was created to help fight against the rapidly mutating virus that has managed to create a resistance to many current AIDS drugs. The once-a-day pill will be available by week's end. Side effects include moderate diarrhea, nausea, vomiting, and flatulence.

In clinical trials of the drug, AIDS patients were found to have significant reduction in the amount of HIV cells in their bloodstream.

Viread is also known as tenofovir disoproxil fumarate.

Information from www.sfgate.com

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content